Conceptio
›
Archive
›
ClinicalTrials.gov
ClinicalTrials.gov
public full text
Iruplinalkib Tablets as Postoperative Adjuvant Therapy in Stage IA ALK-positive NSCLC With High-risk Factors
Tianjin Medical University Cancer Institute and Hospital
· 2026
ClinicalTrials.gov · Datasets · License: Public Domain · 2026
Open Source ↗
nsclc
riskfactors
nsclc, iruplinalkib tablets；alk-positive；nsclc； high-risk factors, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Epilepsy Self-Management for Spanish Speakers: HOBSCOTCH - ESPANOL
#1010984
Pivotal Clinical Trial to Evaluate the Efficacy and Safety After NPNP-001 Application in Patients with Knee Osteoarthritis.
#1010985
Impact on Quality of Life by Moxibustion in Chemotherapy for Cancer
#1010986
Comparison of Spinal Stabilization Exercises Vs Maitland Mobilization Along With Laser Therapy
#1010989
Efficacy of Amplification With Hearing Aids for Tinnitus Relief
#1010991
Record
· ID 811500
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.